Designation of Siltuximab (Sylvant) as an Orphan Drug by Janssen-Cilag Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring that such goods are safe, of high quality, and that their benefits outweigh any risks. The Act was introduced to address the need for a cohesive legal framework governing the approval, quality control, and monitoring of therapeutic goods to protect public health. The Therapeutic Goods Administration (TGA), operating under the auspices of the Commonwealth of Australia's Department of Health, is the body responsible for administering this Act. One of the policy objectives underpinning the Act is to facilitate timely access to therapeutic goods that meet necessary safety and efficacy standards while also encouraging research and development of treatments for rare diseases. The designation of siltuximab (SYLVANT) as an orphan drug on 14 August 2014 under the authority of Dr. Anthony Gill, as the Delegate of the Secretary, exemplifies the Act's intent to support the development and availability of treatments for rare conditions such as multicentric Castleman’s disease (MCD) for specific patient groups.

Scope and Application

The Therapeutic Goods Act 1989, under which this designation operates, applies to therapeutic goods and their regulation in Australia. Specifically, this Act provides the legislative framework for the Therapeutic Goods Administration (TGA) to control the supply, quality, and safety of therapeutic goods, including medicines. The designation of siltuximab (SYLVANT) as an orphan drug under this Act is targeted towards treating a specific condition—multicentric Castleman’s disease (MCD)—in a very specific demographic: adults who are HIV negative and HHV-8 negative. This narrow application underscores the Act's intent to incentivise the development of treatments for rare diseases that otherwise might not attract sufficient investment due to limited market size. The geographic reach of this Act and the resultant designation is national, affecting all entities and persons involved in the manufacture, supply, or approval of therapeutic goods within Australia. The Act’s application extends through subordinate instruments such as the Therapeutic Goods Regulations 1990, which provide further details on orphan drug designation and other regulatory measures.

Key Provisions

The Therapeutic Goods Act 1989, as applied through the Therapeutic Goods Regulations 1990, includes provisions that allow for the designation of certain drugs as orphan drugs. Specifically, under section 16J of the Regulations, a drug can be designated as an orphan drug if it is intended for the treatment of rare diseases or conditions. In this instance, section 16J(2) of the Regulations has been used to designate siltuximab (SYLVANT) as an orphan drug for the treatment of adults with multicentric Castleman’s disease (MCD) who are negative for both human immunodeficiency virus (HIV) and human herpes virus-8 (HHV-8). This designation is effective as of 14 August 2014, as confirmed by Dr. Anthony Gill, Delegate of the Secretary. The designation of siltuximab (SYLVANT) as an orphan drug brings with it certain obligations and requirements under the Act and Regulations. The sponsor of the drug, in this case, Janssen-Cilag Pty Ltd, must ensure that the drug meets the criteria for orphan drug status and that it is appropriately labelled and marketed for its designated use. The sponsor is also responsible for providing the Therapeutic Goods Administration with necessary information and data to support the orphan drug designation, as well as any updates or changes related to the drug’s status or use. Furthermore, the sponsor must comply with any additional requirements or conditions that may be imposed by the Delegate of the Secretary. Failure to comply with the obligations and requirements under the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in significant consequences. The Act and Regulations provide for both civil and criminal penalties for breaches. For instance, section 32 of the Act outlines the civil penalty provisions, which can include fines of up to $222,200 for a corporation and $44,440 for an individual, depending on the nature and severity of the breach. Additionally, section 33 of the Act allows for criminal penalties, including fines of up to $555,500 for a corporation and $111,100 for an individual, along with potential imprisonment terms. These penalties serve as a deterrent against non-compliance and underscore the importance of adhering to the regulatory framework governing therapeutic goods in Australia.